{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:12:57Z","timestamp":1788246777438,"version":"build-2803163510"},"reference-count":32,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"unspecified","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer U.S., LLC.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2025,9,26]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aims to investigate the association between change in urine albumin-to-creatinine ratio (UACR) and clinical outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>Adult patients with elevated UACR (\u226530\u2009mg\/g in initial testing) after the diagnosis of type 2 diabetes and CKD were identified from the Optum electronic health records database (01\/2007\u201309\/2021). UACR change from initial to last test (6\u201324 months) was categorized as &gt;30% decrease, stable (\u221230% to 30%), or &gt;30% increase. Risk of all-cause mortality, composite cardiovascular (CV) outcome (CV death, myocardial infarction, stroke, and hospitalization for heart failure), and CKD progression (\u226540% decline in estimated glomerular filtration rate or kidney failure) were estimated with Cox proportional hazard models adjusted for baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with patients with a stable UACR (n=35\u2009117), those with a &gt;30%\u2009UACR decrease (n=89\u2009562) had lower risk of all-cause mortality (adjusted HR (aHR)=0.93, 95% CI 0.90 to 0.96), composite CV outcomes (aHR=0.93, 95% CI 0.90 to 0.95), and CKD progression (aHR=0.84, 95% CI 0.81 to 0.86) (all p&lt;0.001), and patients with a &gt;30%\u2009UACR increase (n=35\u2009703) had higher risk of each endpoint (aHR=1.24, 95% CI 1.19 to 1.28; aHR=1.24, 95% CI 1.20 to 1.28; and aHR=1.41, 95% CI 1.36 to 1.46, respectively; all p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with CKD and type 2 diabetes, a &gt;30%\u2009UACR decrease was associated with lower risk of mortality, CV events, and CKD progression, whereas a &gt;30%\u2009UACR increase was associated with higher risk of these clinical outcomes. These findings highlight the importance of albuminuria monitoring and potential clinical benefits of targeted UACR reductions in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2024-004854","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:05:16Z","timestamp":1760522716000},"page":"e004854","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5075-6370","authenticated-orcid":false,"given":"Navdeep","family":"Tangri","sequence":"first","affiliation":[{"name":"Department of Community Health Services, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-1909","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-7453","authenticated-orcid":false,"given":"Keith A","family":"Betts","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef MK","family":"Farag","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Beeman","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Du","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon X","family":"Kong","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Williamson","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Li","sequence":"additional","affiliation":[{"name":"Bayer U.S. LLC, Whippany, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aozhou","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Rabideau","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Pantalone","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025101503050572000_13.5.e004854.1","unstructured":"US Centers for Disease Control and Prevention . Diabetes and chronic kidney disease. 2022. Available: https:\/\/www.cdc.gov\/diabetes\/managing\/diabetes-kidney-disease.html#:~:text=Approximately%201%20in%203%20adults,diabetes%20can%20cause%20kidney%20disease.&text=Kidney%20diseases%20are%20the%209th,adults%20with%20diabetes%20has%20CKD"},{"key":"2025101503050572000_13.5.e004854.2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03700417"},{"key":"2025101503050572000_13.5.e004854.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.11.023"},{"key":"2025101503050572000_13.5.e004854.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2322"},{"key":"2025101503050572000_13.5.e004854.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407963"},{"key":"2025101503050572000_13.5.e004854.6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070718"},{"key":"2025101503050572000_13.5.e004854.7","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025101503050572000_13.5.e004854.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"2025101503050572000_13.5.e004854.9","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/eurjpc\/zwaa095","article-title":"Association between albuminuria, incident cardiovascular events, and mortality in persons without hypertension, diabetes, and cardiovascular disease","volume":"29","author":"\u00c4rnl\u00f6v","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2025101503050572000_13.5.e004854.10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025101503050572000_13.5.e004854.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25821","article-title":"Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney Disease","volume":"5","author":"Pasternak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025101503050572000_13.5.e004854.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S011"},{"key":"2025101503050572000_13.5.e004854.13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025101503050572000_13.5.e004854.14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2025101503050572000_13.5.e004854.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4"},{"key":"2025101503050572000_13.5.e004854.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1511-x"},{"key":"2025101503050572000_13.5.e004854.17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-018-0699-7","article-title":"Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease","volume":"17","author":"Pantalone","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2025101503050572000_13.5.e004854.18","unstructured":"Kidney disease: improving global outcomes (kdigo) diabetes work group. kdigo 2020 clinical practice guideline for diabetes management in chronic kidney disease. 2020."},{"key":"2025101503050572000_13.5.e004854.19","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.amjmed.2019.10.042","article-title":"Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study","volume":"133","author":"Fangel","year":"2020","journal-title":"Am J Med"},{"key":"2025101503050572000_13.5.e004854.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040890","article-title":"Urinary albumin-to-creatinine ratio levels are associated with subclinical atherosclerosis and predict CVD events and all-cause deaths: a prospective analysis","volume":"11","author":"Liu","year":"2021","journal-title":"BMJ Open"},{"key":"2025101503050572000_13.5.e004854.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-018-0821-9","article-title":"Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review","volume":"19","author":"Norris","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025101503050572000_13.5.e004854.22","doi-asserted-by":"crossref","unstructured":"Li X , Wu H , Peng H , et al . n.d. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Front Endocrinol 13. doi:10.3389\/fendo.2022.1078686","DOI":"10.3389\/fendo.2022.1078686"},{"key":"2025101503050572000_13.5.e004854.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1622"},{"key":"2025101503050572000_13.5.e004854.24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dom.15030","article-title":"Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes","volume":"25","author":"Palmer","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025101503050572000_13.5.e004854.25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MNH.0000000000000541","article-title":"Change in albuminuria as a surrogate endpoint","volume":"28","author":"Waijer","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025101503050572000_13.5.e004854.26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10157-023-02380-8","article-title":"Association between 1-year changes in urinary albumin-to-creatinine ratio and kidney disease progression in Japanese individuals with diabetes: a historical cohort study","volume":"27","author":"Babazono","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"2025101503050572000_13.5.e004854.27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10157-023-02328-y","article-title":"Changes in urinary albumin as a surrogate for kidney disease progression in people with type 2 diabetes","volume":"27","author":"Yokoyama","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"2025101503050572000_13.5.e004854.28","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025101503050572000_13.5.e004854.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"2025101503050572000_13.5.e004854.30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac157"},{"key":"2025101503050572000_13.5.e004854.31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations","volume":"13","author":"G\u00f3rriz","year":"2022","journal-title":"Diabetes Ther"},{"key":"2025101503050572000_13.5.e004854.32","doi-asserted-by":"crossref","first-page":"638611","DOI":"10.3389\/fphar.2021.638611","article-title":"Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2024-004854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:05:21Z","timestamp":1760522721000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2024-004854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjdrc-2024-004854"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2024-004854","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}